RIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the International Conference on Learning Representations ... Captured by scrape-rss from https://endpoints.news/feed/

MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs ... Captured by scrape-rss from https://endpoints.news/feed/

GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with the media Wednesday. ... Captured by scrape-rss from https://endpoints.news/feed/

Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ... Captured by scrape-rss from https://endpoints.news/feed/

AstraZeneca and the UK government are back in each other's good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a £300 million budget to finish construction of a new office ... Captured by scrape-rss from https://endpoints.news/feed/

AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for. Its first-quarter Captured by scrape-rss from https://endpoints.news/feed/

Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and research, because that part ... Captured by scrape-rss from https://endpoints.news/feed/

The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma giant has signed ... Captured by scrape-rss from https://endpoints.news/feed/

A few years in, admin tech is still reigning as the king of health tech funding. Startups using AI to tackle mundane administrative work in healthcare, such as follow-ups, Captured by scrape-rss from https://endpoints.news/feed/

Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ... Captured by scrape-rss from https://endpoints.news/feed/

Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a heart ... Captured by scrape-rss from https://endpoints.news/feed/

Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to slash its healthcare ... Captured by scrape-rss from https://endpoints.news/feed/

Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwired to target specific stretches of bacterial ... Captured by scrape-rss from https://endpoints.news/feed/

Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ... Captured by scrape-rss from https://endpoints.news/feed/

When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications on how new generics get ... Captured by scrape-rss from https://endpoints.news/feed/

Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune diseases. The Tuesday morning Series ... Captured by scrape-rss from https://endpoints.news/feed/

The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as it flows in, the agency announced Tuesday. AstraZeneca and Amgen ... Captured by scrape-rss from https://endpoints.news/feed/

The FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New information shows that the ... Captured by scrape-rss from https://endpoints.news/feed/

Devoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athenahealth executives and an ... Captured by scrape-rss from https://endpoints.news/feed/

Obesity patients taking the weight loss injection being developed by Boehringer Ingelheim lost nearly 17% of their weight after about a year and a half, the company said Tuesday. The results are more or less ... Captured by scrape-rss from https://endpoints.news/feed/

The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and option deal with ... Captured by scrape-rss from https://endpoints.news/feed/

RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a top machine ... Captured by scrape-rss from https://endpoints.news/feed/

Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers over its cancer drug ... Captured by scrape-rss from https://endpoints.news/feed/

After a new drug from Revolution Medicines reignited hopes for treating pancreatic cancer, a rival compound from Erasca — which released early-stage data on Monday — could prompt a legal showdown between the biotechs. And it did ... Captured by scrape-rss from https://endpoints.news/feed/